Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

Milton Keynes Health Economy

Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. Version 18. July 2017
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	***Date of TA Release***	***Availability of medicine for NHS patients with this medical condition, as indicated by NICE***	***Adherence of local formulary to NICE***				
			Yes *(mark 'x' if applicable)*	***N/A*** *(mark 'x' if applicable)*	***Date of local decision*** *(DD/MM/YY)*	***Time to implement*** *(days)*	***Notes*** *(e.g. rationale, method of making available)*
2017/2018							
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)	7/5/2017	**Daratumumab** - was unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag	x		7/26/2017	21	Terminated Appraisal by NICE
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)	7/5/2017	**Bortezomib** - was unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no evidence submission was received from Janssen-Cilag	x		7/26/2017	21	Terminated Appraisal by NICE
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)	7/5/2017	**Ibrutinib** - was unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from Janssen–Cilag	x		7/26/2017	21	Terminated Appraisal by NICE
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)	6/28/2017	**Ponatinib (Iclusig)** is recommended, within its marketing authorisation, as an option for treating chronic-, accelerated- or blast-phase chronic myeloid leukaemia in adults	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)	6/28/2017	**Blinatumomab (Blincyto)** is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)	6/28/2017	**Everolimus (Afinitor) and Sunitinib (Sutent)** are recommended, within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Etelcalcetide for treating secondary hyperparathyroidism (TA448)	6/28/2017	**Etelcalcetide (Parsabiv)** is recommended as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)	6/28/2017	**Pembrolizumab (Keytruda)** is recommended for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)	6/28/2017	**Brentuximab vedotin (Adcetris)** is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults	x		7/26/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)	5/24/2017	**Certolizumab pegol (Cimzia) alone, or in combination with methotrexate** is recommended as an option for treating active psoriatic arthritis in adults	x		7/26/2017	63	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)	3/22/2017	**Tenofovir alafenamide** - was unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from	x		5/24/2017	63	Terminated Appraisal by NICE
Obeticholic acid for treating primary biliary cholangitis (TA443)	4/26/2017	**Obeticholic acid (Ocaliva)** is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme.	x		5/24/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)	4/26/2017	Ixekizumab (Taltz) is recommended as an option for treating plaque psoriasis in adults	x		5/24/2017	28	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)	4/26/2017	**Daclizumab (Zinbryta)** is recommended as an option for treating multiple sclerosis in adults	x		5/24/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)	4/26/2017	**Pegylated liposomal irinotecan (Onivyde)**, in combination with 5-fluorouracil and leucovorin, is not recommended, within its marketing authorisation, for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.	x		5/24/2017	28	Not recommended
			15	0			
			% "Yes"	**% "N/A"**	_	**Average implement time** (days)	
Adherence statistics for 2017-18			100%	0%		**31**	